<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02558803</url>
  </required_header>
  <id_info>
    <org_study_id>Merck 21</org_study_id>
    <nct_id>NCT02558803</nct_id>
  </id_info>
  <brief_title>HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 &amp; 3</brief_title>
  <official_title>HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 &amp; 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenstrief Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Regenstrief Institute, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, 2-arm observational study. The 2 arms (randomized at the level of health care
      provider) will be: 1. usual practice; 2. automated reminders to recommend 2nd and 3rd doses
      of HPV vaccine for eligible male and female adolescents who have initiated vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team plans to conduct a randomized clinical trial with three arms: (1) usual care,
      (2) the simple reminder, and (3) the simple reminder plus the script. Randomization will be
      carried out at the physician level at each clinical site, to ensure that all three treatment
      arms are represented in each clinic. The primary outcome, HPV vaccine acceptance, will be
      assessed for each study participant.

      This study will be implemented through the Child Health Improvement through Computer
      Automation system (CHICA). CHICA is a computer based clinical decision support system that
      has been operating in the Wishard/Eskenazi system since 2004. CHICA now operates in 5 clinics
      in the health system and has served well over 37,000 children. CHICA supports primary
      pediatric care, supporting screening, counseling, anticipatory guidance, vaccinations, and
      chronic disease diagnosis and management.

      CHICA is unique in several respects. These include a unique tailored, scannable paper
      interface, a prioritization scheme that assures the highest priority reminders are given to
      physicians, and the ability to collect data directly from families in the waiting room. CHICA
      acts as a front end to the Regenstrief Medical Record System (RMRS), the electronic medical
      record for the Eskenazi health system. The RMRS and CHICA communicate using industry standard
      HL7 communication protocols.

      When a patient checks into a CHICA clinic, CHICA receives an HL7 ADT (registration) message.
      In response CHICA requests a download of the patient's record from the RMRS. CHICA applies a
      set of Arden Syntax rules to the patient's data to select 20 yes/no questions that are
      printed. The family answers these questions by checking boxes. The nurse or medical assistant
      enters height, weight, etc. on the same form and the form is scanned. The data enter CHICA's
      database through optical mark recognition and optical character recognition. Recently we have
      begun converting from this scannable paper format to electronic tablets.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of physician-targeted automated HPV vaccination reminders on 2nd and 3rd dose HPV vaccination rates among 11-17 year old male and female patients</measure>
    <time_frame>Six Months</time_frame>
    <description>To evaluate the rate of physician-targeted automated HPV vaccination reminders on 2nd and 3rd dose HPV vaccination rates among 11-17 year old male and female patients who have received 1 or 2 doses of vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Physician Acceptance of the Prompts</measure>
    <time_frame>Six Months</time_frame>
    <description>The study team will compare changes in vaccination rates with qualitative feedback from providers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1305</enrollment>
  <condition>Human Papilloma Virus Infection Type 11</condition>
  <condition>Human Papilloma Virus Infection Type 16</condition>
  <condition>Human Papilloma Virus Infection Type 18</condition>
  <condition>Human Papilloma Virus Infection Type 6</condition>
  <condition>Cervical Cancer</condition>
  <condition>Genital Warts</condition>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The clinical team will be left to identify the need for a follow-up HPV vaccine through existing mechanisms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple Reminder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Simple Reminder</intervention_name>
    <description>A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.</description>
    <arm_group_label>Simple Reminder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Provider Criteria

          -  All pediatricians and nurse practitioners who provide health care at the 5 CHICA
             clinics will be included in this study

        Subject Criteria

          -  Patients will be 11-17 year old

          -  Males and females

          -  A visit to at least one of the five CHICA clinics

          -  Eligible for the 2nd or 3rd dose of HPV vaccine

        Exclusion Criteria:

          -  Patients in the eligible age range who have not started or have completed the HPV
             vaccine series will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory D Zimet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eskenazi Health Outpatient Care Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health Center Blackburn</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health Center Forest Manor</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health West 38th Street</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eskenazi Health Center Pecar</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25. Review.</citation>
    <PMID>16949997</PMID>
  </reference>
  <reference>
    <citation>Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol. 2010 May;117(2 Suppl):S15-9. doi: 10.1016/j.ygyno.2010.01.026. Epub 2010 Feb 6. Review.</citation>
    <PMID>20138345</PMID>
  </reference>
  <reference>
    <citation>Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010 Apr;46(4 Suppl):S20-6. doi: 10.1016/j.jadohealth.2010.01.016.</citation>
    <PMID>20307840</PMID>
  </reference>
  <reference>
    <citation>Haupt RM, Sings HL. The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. J Adolesc Health. 2011 Nov;49(5):467-75. doi: 10.1016/j.jadohealth.2011.07.003. Epub 2011 Sep 9.</citation>
    <PMID>22018560</PMID>
  </reference>
  <reference>
    <citation>Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013 Oct 9;347:f5906. doi: 10.1136/bmj.f5906.</citation>
    <PMID>24108159</PMID>
  </reference>
  <reference>
    <citation>Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, Hviid A. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015 Jan 6;313(1):54-61. doi: 10.1001/jama.2014.16946.</citation>
    <PMID>25562266</PMID>
  </reference>
  <reference>
    <citation>Ojha RP, Jackson BE, Tota JE, Offutt-Powell TN, Singh KP, Bae S. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother. 2014;10(1):232-7. doi: 10.4161/hv.26292. Epub 2013 Sep 6.</citation>
    <PMID>24013368</PMID>
  </reference>
  <reference>
    <citation>Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, Cheetham TC, Liaw KL, Takhar H, Jacobsen SJ. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012 Dec;166(12):1140-8. doi: 10.1001/archpediatrics.2012.1451.</citation>
    <PMID>23027469</PMID>
  </reference>
  <reference>
    <citation>Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH, Spiessens B, Descamps D, Hardt K, Lehtinen M, Dubin G; HPV Vaccine Adolescent Study Investigators Network. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007 Jun;40(6):564-71.</citation>
    <PMID>17531764</PMID>
  </reference>
  <reference>
    <citation>Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, Puchalski D, Giacoletti KE, Sings HL, Lukac S, Alvarez FB, Barr E. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007 Mar;26(3):201-9.</citation>
    <PMID>17484215</PMID>
  </reference>
  <reference>
    <citation>Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013 Feb;40(2):130-5. doi: 10.1097/OLQ.0b013e31827bd66b.</citation>
    <PMID>23324976</PMID>
  </reference>
  <reference>
    <citation>Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013 Apr 18;346:f2032. doi: 10.1136/bmj.f2032. Erratum in: BMJ. 2013;346:F2942.</citation>
    <PMID>23599298</PMID>
  </reference>
  <reference>
    <citation>Ali H, Guy RJ, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Donovan B. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013 Mar 18;13:140. doi: 10.1186/1471-2334-13-140.</citation>
    <PMID>23506489</PMID>
  </reference>
  <reference>
    <citation>Elam-Evans LD, Yankey D, Jeyarajah J, Singleton JA, Curtis RC, MacNeil J, Hariri S; Immunization Services Division, National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention (CDC). National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013. MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):625-33.</citation>
    <PMID>25055186</PMID>
  </reference>
  <reference>
    <citation>Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, Markowitz L, Smith JS. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis. 2011 Mar;38(3):197-204. doi: 10.1097/OLQ.0b013e3181f12dbf.</citation>
    <PMID>20838362</PMID>
  </reference>
  <reference>
    <citation>Guerry SL, De Rosa CJ, Markowitz LE, Walker S, Liddon N, Kerndt PR, Gottlieb SL. Human papillomavirus vaccine initiation among adolescent girls in high-risk communities. Vaccine. 2011 Mar 9;29(12):2235-41. doi: 10.1016/j.vaccine.2011.01.052. Epub 2011 Feb 1.</citation>
    <PMID>21288799</PMID>
  </reference>
  <reference>
    <citation>Donahue KL, Stupiansky NW, Alexander AB, Zimet GD. Acceptability of the human papillomavirus vaccine and reasons for non-vaccination among parents of adolescent sons. Vaccine. 2014 Jun 30;32(31):3883-5. doi: 10.1016/j.vaccine.2014.05.035. Epub 2014 May 18.</citation>
    <PMID>24844150</PMID>
  </reference>
  <reference>
    <citation>Kester LM, Zimet GD, Fortenberry JD, Kahn JA, Shew ML. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J. 2013 Jul;17(5):879-85. doi: 10.1007/s10995-012-1066-z.</citation>
    <PMID>22729660</PMID>
  </reference>
  <reference>
    <citation>Vadaparampil ST, Kahn JA, Salmon D, Lee JH, Quinn GP, Roetzheim R, Bruder K, Malo TL, Proveaux T, Zhao X, Halsey N, Giuliano AR. Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine. 2011 Nov 3;29(47):8634-41. doi: 10.1016/j.vaccine.2011.09.006. Epub 2011 Sep 14.</citation>
    <PMID>21924315</PMID>
  </reference>
  <reference>
    <citation>Evans, G. and A. Bostrom, The evolution of vaccine risk communication in the United States: 1982-2002, in Jordan report 20th anniversary: Accelerated development of vaccines 2002, A. National Institute of and D. Infectious, Editors. 2002, U.S. Department of Health and Human Services, National Institute of Allergy and Infectious Diseases: Washington, D.C. p. 58-71.</citation>
  </reference>
  <reference>
    <citation>Esposito S, Bosis S, Pelucchi C, Begliatti E, Rognoni A, Bellasio M, Tel F, Consolo S, Principi N. Pediatrician knowledge and attitudes regarding human papillomavirus disease and its prevention. Vaccine. 2007 Aug 29;25(35):6437-46. Epub 2007 Jul 16.</citation>
    <PMID>17673339</PMID>
  </reference>
  <reference>
    <citation>Schnatz PF, Humphrey K, O'Sullivan DM. Assessment of the perceptions and administration of the human papillomavirus vaccine. J Low Genit Tract Dis. 2010 Apr;14(2):103-7. doi: 10.1097/LGT.0b013e3181b240ca.</citation>
    <PMID>20354417</PMID>
  </reference>
  <reference>
    <citation>Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health. 2005 Dec;37(6 Suppl):S10-6. Review.</citation>
    <PMID>16310136</PMID>
  </reference>
  <reference>
    <citation>Ko EM, Missmer S, Johnson NR. Physician attitudes and practice toward human papillomavirus vaccination. J Low Genit Tract Dis. 2010 Oct;14(4):339-45. doi: 10.1097/LGT.0b013e3181dca59c.</citation>
    <PMID>20885162</PMID>
  </reference>
  <reference>
    <citation>Carroll AE, Bauer NS, Dugan TM, Anand V, Saha C, Downs SM. Use of a computerized decision aid for ADHD diagnosis: a randomized controlled trial. Pediatrics. 2013 Sep;132(3):e623-9. doi: 10.1542/peds.2013-0933. Epub 2013 Aug 19.</citation>
    <PMID>23958768</PMID>
  </reference>
  <reference>
    <citation>Carroll AE, Biondich P, Anand V, Dugan TM, Downs SM. A randomized controlled trial of screening for maternal depression with a clinical decision support system. J Am Med Inform Assoc. 2013 Mar-Apr;20(2):311-6. doi: 10.1136/amiajnl-2011-000682. Epub 2012 Jun 28.</citation>
    <PMID>22744960</PMID>
  </reference>
  <reference>
    <citation>Carroll AE, Biondich PG, Anand V, Dugan TM, Sheley ME, Xu SZ, Downs SM. Targeted screening for pediatric conditions with the CHICA system. J Am Med Inform Assoc. 2011 Jul-Aug;18(4):485-90. doi: 10.1136/amiajnl-2011-000088.</citation>
    <PMID>21672910</PMID>
  </reference>
  <reference>
    <citation>Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine. 2014 Apr 7;32(17):1901-20. doi: 10.1016/j.vaccine.2014.01.091. Epub 2014 Feb 14. Review.</citation>
    <PMID>24530401</PMID>
  </reference>
  <reference>
    <citation>Mayne SL, duRivage NE, Feemster KA, Localio AR, Grundmeier RW, Fiks AG. Effect of decision support on missed opportunities for human papillomavirus vaccination. Am J Prev Med. 2014 Dec;47(6):734-44. doi: 10.1016/j.amepre.2014.08.010. Epub 2014 Nov 18.</citation>
    <PMID>25455116</PMID>
  </reference>
  <reference>
    <citation>Fiks AG, Grundmeier RW, Mayne S, Song L, Feemster K, Karavite D, Hughes CC, Massey J, Keren R, Bell LM, Wasserman R, Localio AR. Effectiveness of decision support for families, clinicians, or both on HPV vaccine receipt. Pediatrics. 2013 Jun;131(6):1114-24. doi: 10.1542/peds.2012-3122. Epub 2013 May 6.</citation>
    <PMID>23650297</PMID>
  </reference>
  <reference>
    <citation>Perkins RB, Zisblatt L, Legler A, Trucks E, Hanchate A, Gorin SS. Effectiveness of a provider-focused intervention to improve HPV vaccination rates in boys and girls. Vaccine. 2015 Feb 25;33(9):1223-9. doi: 10.1016/j.vaccine.2014.11.021. Epub 2014 Nov 24.</citation>
    <PMID>25448095</PMID>
  </reference>
  <reference>
    <citation>Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013 Aug 1;208(3):385-93. doi: 10.1093/infdis/jit192. Epub 2013 Jun 19.</citation>
    <PMID>23785124</PMID>
  </reference>
  <reference>
    <citation>Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013 Nov;57(5):414-8. doi: 10.1016/j.ypmed.2013.05.013. Epub 2013 May 31.</citation>
    <PMID>23732252</PMID>
  </reference>
  <reference>
    <citation>Shojania KG, Jennings A, Mayhew A, Ramsay CR, Eccles MP, Grimshaw J. The effects of on-screen, point of care computer reminders on processes and outcomes of care. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD001096. doi: 10.1002/14651858.CD001096.pub2. Review.</citation>
    <PMID>19588323</PMID>
  </reference>
  <reference>
    <citation>Greenhalgh T, Robert G, Macfarlane F, Bate P, Kyriakidou O. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581-629. Review.</citation>
    <PMID>15595944</PMID>
  </reference>
  <reference>
    <citation>Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009 Aug 7;4:50. doi: 10.1186/1748-5908-4-50.</citation>
    <PMID>19664226</PMID>
  </reference>
  <reference>
    <citation>Anand V, Biondich PG, Liu G, Rosenman M, Downs SM. Child Health Improvement through Computer Automation: the CHICA system. Stud Health Technol Inform. 2004;107(Pt 1):187-91.</citation>
    <PMID>15360800</PMID>
  </reference>
  <reference>
    <citation>Anand V, Carroll AE, Downs SM. Automated primary care screening in pediatric waiting rooms. Pediatrics. 2012 May;129(5):e1275-81. doi: 10.1542/peds.2011-2875. Epub 2012 Apr 16.</citation>
    <PMID>22508925</PMID>
  </reference>
  <reference>
    <citation>Biondich PG, Downs SM, Anand V, Carroll AE. Automating the recognition and prioritization of needed preventive services: early results from the CHICA system. AMIA Annu Symp Proc. 2005:51-5.</citation>
    <PMID>16779000</PMID>
  </reference>
  <reference>
    <citation>Downs SM, Uner H. Expected value prioritization of prompts and reminders. Proc AMIA Symp. 2002:215-9.</citation>
    <PMID>12463818</PMID>
  </reference>
  <reference>
    <citation>Downs SM, Zhu V, Anand V, Biondich PG, Carroll AE. The CHICA smoking cessation system. AMIA Annu Symp Proc. 2008 Nov 6:166-70.</citation>
    <PMID>18998823</PMID>
  </reference>
  <reference>
    <citation>Bauer, N.S., et al., Computer Decision Support to Improve Autism Screening and Care in Community Pediatric Clinics. Infants &amp; Young Children, 2013. 26(4): p. 306-317.</citation>
  </reference>
  <reference>
    <citation>Denzin, N.K. and Y.S. Lincoln, The Sage handbook of qualitative research. Vol. 4th. 2011, Thousand Oaks, CA: Sage.</citation>
  </reference>
  <reference>
    <citation>Braun, V. and V. Clarke, Using thematic analysis in psychology. Qualitative Research in Psychology, 2006. 3: p. 77-101.</citation>
  </reference>
  <reference>
    <citation>Fleiss JL, Tytun A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics. 1980 Jun;36(2):343-6.</citation>
    <PMID>26625475</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV Vaccinations</keyword>
  <keyword>Quadrivalent Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Condylomata Acuminata</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual provider data will not be made available.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>May 3, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

